Muscle-invasive Bladder Cancer in Elderly and Frail People: Is Hypofractionated Radiotherapy a Feasible Approach when No Other Local Options Are Available?

Overview

Journal Tumori

Publisher Sage Publications

Specialty Oncology

Date 2024 May 10

PMID 38726748

Authors

Giulia Marvaso

Angelo Vitullo

Giulia Corrao

Maria Giulia Vincini

Mattia Zaffaroni

Riccardo Villa

Federico Mastroleo

Lukasz Kuncman

Dario Zerini

Ilaria Repetti

Chiara Lorubbio

Gennaro Musi

Ottavio de Cobelli

Barbara Alicja Jereczek-Fossa

Affiliations

Soon will be listed here.

Abstract

Aim: The study aims to report the feasibility and safety of palliative hypofractionated radiotherapy targeting macroscopic bladder tumors in a monocentric cohort of frail and elderly bladder cancer patients not eligible for curative treatments.

Methods: Patients who underwent hypofractionated radiotherapy to the gross disease or to the tumor bed after transurethral resection of bladder tumor from 2017 to 2021 at the European Institute of Oncology IRCCS, were retrospectively considered. Schedules of treatment were 30 and 25 Gy in 5 fractions (both every other day, and consecutive days). Treatment response was evaluated with radiological investigation and/or cystoscopy. Toxicity assessment was carried out according to RTOG/EORTC v2.0 criteria.

Results: A total of 16 patients were included in the study, of these 11 received hypofractionated radiotherapy on the macroscopic target volume and five on the tumor bed after transurethral resection of bladder tumor. No grade (G) >2 acute toxicities were described after treatment for both groups. Only one patient in the group receiving radiotherapy on the macroscopic disease reported G4 GU late toxicity. Ten patients had available follow-up status (median FU time 18 months), of them six had complete response, one had stable disease, and three had progression of disease. The overall response rate and disease control rate were 60% and 70%, respectively.

Conclusion: Our preliminary data demonstrate that palliative hypofractionated radiotherapy for bladder cancer in a frail and elderly population is technically feasible, with an acceptable toxicity profile. These outcomes emphasize the potential of this approach in a non-radical setting and could help to provide more solid indications in this underrepresented setting of patients.

References

. Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials. Eur Urol. 2021; 81(1):50-61. PMC: 8708165. DOI: 10.1016/j.eururo.2021.09.028. View

Magee D, Cheung D, Hird A, Sridhar S, Catton C, Chung P . Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model. Can Urol Assoc J. 2021; 16(4):E197-E204. PMC: 9054325. DOI: 10.5489/cuaj.7453. View

Duchesne G, Bolger J, Griffiths G, Roberts J, Graham J, Hoskin P . A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. Int J Radiat Oncol Biol Phys. 2000; 47(2):379-88. DOI: 10.1016/s0360-3016(00)00430-2. View

Novara G, Catto J, Wilson T, Annerstedt M, Chan K, Murphy D . Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy. Eur Urol. 2015; 67(3):376-401. DOI: 10.1016/j.eururo.2014.12.007. View

Babjuk M, Burger M, Capoun O, Cohen D, Comperat E, Dominguez Escrig J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2021; 81(1):75-94. DOI: 10.1016/j.eururo.2021.08.010. View

Huddart R, Birtle A, Maynard L, Beresford M, Blazeby J, Donovan J . Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy. BJU Int. 2017; 120(5):639-650. PMC: 5655733. DOI: 10.1111/bju.13900. View

Huddart R, Hafeez S, Omar A, Alonzi R, Birtle A, Cheung K . Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial. Clin Oncol (R Coll Radiol). 2023; 35(9):586-597. DOI: 10.1016/j.clon.2023.05.002. View

Hasan S, Galvan E, Shaver C, Hermans M, Ha C, Swanson G . Outcomes of patients undergoing radiation therapy for bladder cancer. Bladder (San Franc). 2020; 5(4):e37. PMC: 7401990. DOI: 10.14440/bladder.2018.785. View

Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K . Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000; 47(1):13-47. DOI: 10.1016/s0360-3016(99)00559-3. View

10.

Jereczek-Fossa B, Marvaso G . Palliative radiation therapy in bladder cancer: a matter of dose, techniques and patients' selection. Ann Palliat Med. 2019; 8(5):786-789. DOI: 10.21037/apm.2019.11.02. View

11.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

12.

Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L . Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2006; 66(6 Suppl 1):4-34. DOI: 10.1016/j.urology.2005.07.062. View

13.

Noon A, Albertsen P, Thomas F, Rosario D, Catto J . Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients. Br J Cancer. 2013; 108(7):1534-40. PMC: 3629420. DOI: 10.1038/bjc.2013.106. View

14.

Bamias A, Stenzl A, Brown S, Albiges L, Babjuk M, Birtle A . Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty. Eur Urol. 2023; 84(4):381-389. DOI: 10.1016/j.eururo.2023.05.005. View

15.

Softness K, Kaul S, Fleishman A, Efstathiou J, Bellmunt J, Kim S . Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder. Urol Oncol. 2022; 40(6):272.e1-272.e9. DOI: 10.1016/j.urolonc.2021.12.015. View

16.

Kaushik D, Shi Z, Liss M, Wang H, Jha R, Choi B . Screening logs from a pilot randomized controlled trial of radical cystectomy versus chemoradiation therapy for muscle-invasive bladder cancer. Urol Oncol. 2019; 38(1):4.e1-4.e6. PMC: 7003712. DOI: 10.1016/j.urolonc.2019.09.008. View

17.

Zlotta A, Ballas L, Niemierko A, Lajkosz K, Kuk C, Miranda G . Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 2023; 24(6):669-681. DOI: 10.1016/S1470-2045(23)00170-5. View

18.

Chen L, Suy S, Uhm S, Oermann E, Ju A, Chen V . Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013; 8:58. PMC: 3610192. DOI: 10.1186/1748-717X-8-58. View

19.

Fahmy O, Khairul-Asri M, Schubert T, Renninger M, Malek R, Kubler H . A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2017; 36(2):43-53. DOI: 10.1016/j.urolonc.2017.10.002. View

20.

Folkert M, Timmerman R . Stereotactic ablative body radiosurgery (SABR) or Stereotactic body radiation therapy (SBRT). Adv Drug Deliv Rev. 2016; 109:3-14. DOI: 10.1016/j.addr.2016.11.005. View